Clavamox Tabs 125mg
Clavamox (amoxicillin trihydrate/clavulanate potassium) is indicated in the treatment of the following conditions.
DOGS
� Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: beta-lactamase-producing Staphylococcus aureus, non-beta-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.
� Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
CATS
� Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: beta-lactamase-producing Staphylococcus aureus, non-beta-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp.
� Urinary tract infections (cystitis) due to susceptible strains of E. coli.
CLAVAMOX�
Zoetis
(amoxicillin trihydrate/clavulanate potassium)
Veterinary Tablets
For use in dogs and cats
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
DESCRIPTION: Clavamox (amoxicillin trihydrate/clavulanate potassium) is an orally administered formulation comprised of the broad-spectrum antibiotic Amoxi� (amoxicillin trihydrate) and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).
Amoxicillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative, aerobic and anaerobic microorganisms. It does not resist destruction by β-lactamases; therefore, it is not effective against β-lactamase-producing bacteria. Chemically, it is D(-)-α-amino-p-hydroxybenzyl penicillin trihydrate.
Clavulanic acid, an inhibitor of β-lactamase enzymes, is produced by the fermentation of Streptomyces clavuligerus. Clavulanic acid by itself has only weak antibacterial activity. Chemically, clavulanate potassium is potassium z-(3R,5R)-2-β-hydroxyethylidene clavam-3-carboxylate.
ACTIONS: Clavamox is stable in the presence of gastric acid and is not significantly influenced by gastric or intestinal contents. The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.
INDICATIONS: Clavamox Tablets are indicated in the treatment of:
Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.
Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Clavamox has been shown to be clinically effective for treating cases of canine periodontal disease.
Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
Therapy may be initiated with Clavamox prior to obtaining results from bacteriological and susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the organisms to Clavamox. Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated.
CONTRAINDICATIONS: The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.
WARNINGS: Safety of use in pregnant or breeding animals has not been determined. Store in a dry, cool place at temperatures not above 25�C (77�F).
Do not remove from foil strip until ready to use.
ADVERSE REACTIONS: Clavamox contains a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.
DOSAGE AND ADMINISTRATION:
Dogs: The recommended dosage is 6.25 mg/lb of body weight twice a day.
Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
Cats: The recommended dosage is 62.5 mg twice a day.
Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.
Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.
HOW SUPPLIED: Clavamox Tablets in the following strengths are supplied in strip packs. Each carton holds 15 strips with 14 tablets per strip (210 tablets per carton).
Each 62.5-mg tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin activity and 12.5 mg of clavulanic acid as the potassium salt. For use in dogs and cats.
Each 125-mg tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin activity and 25 mg of clavulanic acid as the potassium salt. For use in dogs only.
Each 250-mg tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin activity and 50 mg of clavulanic acid as the potassium salt. For use in dogs only.
Each 375-mg tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin activity and 75 mg of clavulanic acid as the potassium salt. For use in dogs only.